The Iris and Junming Le Foundation was founded in 2006 to further health initiatives in research and patient care. The Le Foundation believes that providing support to medical professionals engaged in research guarantees the sustained pursuit of innovation that leads to wide-ranging improvements in health. Furthermore, involving future generations and instilling a passion for medical discovery secures the development of new researchers armed to solve the problems of tomorrow.
Funding for The Le Foundation is mainly provided by a royalty stream from the invention of Remicade in 1989 by Dr. Junming Le, Adjunct Associate Professor of Microbiology, New York University School of Medicine. Remicade is a new class of medicine effectively treating a number of autoimmune diseases including rheumatoid arthritis, psoriasis, Crohn's disease, and is currently manufactured and marketed by Johnson & Johnson and Merck. Additionally, The Le Foundation actively seeks various investment opportunities, such as real estate and acquisitions, in order to enhance its diversified financial portfolio.
The Iris and Junming Le Foundation has been involved with the following programs:
Dr. Junming Le, Chairman and Director
Iris Le (Sai Hong Yan), Director
Daniella Ann Loh, Director
Roslyn Ceresne, Financial Market Real Estate Analyst
Uri Weg, Manager
Please contact us with any comments, questions, or suggestions.The Iris and Junming Le Foundation